ASCO Review 2016 Colorectal Cancer
-
Upload
osuccc-james -
Category
Healthcare
-
view
2.114 -
download
0
Transcript of ASCO Review 2016 Colorectal Cancer
![Page 1: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/1.jpg)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Updates in Colorectal Cancer 2016 Kristen K. Ciombor, MD, MSCI Assistant Professor Division of Medical Oncology
![Page 2: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/2.jpg)
Outline § Primary tumor sidedness in colorectal cancer
§ CALGB/SWOG 80405
§ Immunotherapy in colorectal and anal cancer § Immunoscore in early stage colon cancer § Pembrolizumab in MSI-H mCRC § Nivolumab +/- ipilimumab in mCRC § Cobimetinib + atezolizumab in MSS mCRC § Nivolumab in metastatic anal cancer
2
![Page 3: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/3.jpg)
Primary Tumor Sidedness in Colorectal Cancer (CRC)
3
![Page 4: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/4.jpg)
Impact of primary tumor location on Overall Survival and Progression Free Survival in patients with metastatic colorectal cancer: Analysis of CALGB/SWOG 80405 (Alliance)
A Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O’Neil, J Shaw, J Atkins, LE Horvath, B Polite, JA Meyerhardt, EM O’Reilly, R Goldberg, HS Hochster, CD Blanke, R Schilsky, RJ Mayer, M Bertagnolli, HJ Lenz for SWOG and the ALLIANCE
![Page 5: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/5.jpg)
CALGB/SWOG 80405 Chemo + Cetuximab
Chemo + Bevacizumab
1ST LINE
MET / ADVANCED COLORECTAL
KRAS wt
FOLFIRI or
FOLFOX
MD choice
ASCO, JUNE, 2014 Chemo + Cetuximab OS = 32.0 mos PFS = 11.4 mos
Chemo + Bevacizumab OS = 31.2 mos PFS = 11.3 mos N = 1137
CONCLUSION: NO DIFFERENCE
OS better than anticipated in both arms: Treatment effect and/or Patient selection
All RAS wt
ESMO, SEP, 2014
N = 526
![Page 6: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/6.jpg)
CALGB 80405: Side of primary tumor Methods • Population
– KRAS wt pts in main analysis – Pre-amendment KRAS mut pts
• Data extraction – Study chart, other supporting information if available
• Side of 1° determination – Definitive information:
• Colonoscopy, surgical or imaging report Presented by:
![Page 7: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/7.jpg)
Presented by:
80405: Side of Primary Tumors
LEFT N = 732 (68%)
RIGHT N = 293 (27%)
TRANSVERSE N = 66
COULD NOT DETERMINE N = 46
![Page 8: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/8.jpg)
Bettington, et al. Histopathology. 2013.
Embryology: The origin of the colon
RIGHT COLON
LEFT COLON
![Page 9: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/9.jpg)
80405: Overall Survival by Sidedness
Presented by:
Side N (Events) Median
(95% CI)
HR
(95% CI) p
Left 732 (550) 33.3
(31.4-35.7) 1.55
(1.32-1.82) < 0.0001
Right 293 (242) 19.4
(16.7-23.6)
Right
Left
![Page 10: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/10.jpg)
80405: OS by Sidedness (Bevacizumab)
Presented by:
Side N (Events) Median
(95% CI) HR(95% CI) p
Left 356 (280) 31.4
(28.3-33.6) 1.32
(1.05-1.65)
0.01
Right 150 (121)
24.2
(17.9-30.3)
Left Right
![Page 11: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/11.jpg)
80405: OS by Sidedness (Cetuximab)
Presented by:
Side N (Events) Median
(95% CI)
HR
(95% CI) p
Left 376 (270) 36.0
(32.6-40.3) 1.87
(1.48-2.32)
<0.0001
Right 143 (121)
16.7
(13.1-19.4)
Left
Right
![Page 12: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/12.jpg)
80405: Sidedness is Prognostic Overall Survival (OS)
Presented by:
KRAS wt N = 1025
Right 1° Median OS
(mos)
Left 1° Median OS
(mos)
Hazard Ratio 95% CI
(adjusted*) P (adjusted*)
All pts 19.4 33.3 1.55 (1.32,1.82) P < 0.0001
Cet 16.7 36.0 1.87 (1.48, 2.32) P < 0.0001
Bev 24.2 31.4 1.32 (1.05, 1.65) P = 0.01
*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastases
19.3 MONTHS IS A BIG DIFFERENCE !!
![Page 13: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/13.jpg)
80405: Overall Survival by Sidedness and Biologic
Presented by:
31.4 (28.3-33.6)
36.0 (32.6-40.3)
24.2 (17.9-30.3)
16.7 (13.1-19.4)
![Page 14: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/14.jpg)
Summary of Primary Tumor Sidedness in mCRC § Patients with R-sided primaries had much worse
outcomes than pts with L-sided primaries, independent of biologic arm (prognostic)
§ 1st line cetuximab and bevacizumab have different treatment effects in sidedness subgroups
§ Sidedness is likely a surrogate for tumor biology § Future trials to stratify patients by primary sidedness § Remember: this is a retrospective ad hoc analysis;
these results will factor in when making tx decisions but this is not the whole story
14
![Page 15: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/15.jpg)
Immunoscore in Early Stage Colon Cancer
15
![Page 16: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/16.jpg)
Slide 1
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 17: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/17.jpg)
Slide 6
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 18: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/18.jpg)
Slide 11
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 19: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/19.jpg)
Slide 14
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 20: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/20.jpg)
Slide 18
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 21: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/21.jpg)
Slide 22
Presented By Jerome Galon at 2016 ASCO Annual Meeting
![Page 22: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/22.jpg)
Summary of Immunoscore in Early Stage Colon CA § Time to recurrence was significantly longer in patients
with stage I/II/III colon cancer and high immunoscore § Immunoscore is significant in multivariate analyses in all
cohorts (TS, IVS, EVS) § Potential identification of a high-risk stage II group § Immunoscore predicts TTR, DFS and OS § How much is microsatellite instability contributing? § Future immune-based assay for cancer: TNM-Immune?
22
![Page 23: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/23.jpg)
Pembrolizumab in MSI-H mCRC
23
![Page 24: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/24.jpg)
Slide 1
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 25: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/25.jpg)
Slide 2
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 26: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/26.jpg)
Slide 5
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 27: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/27.jpg)
Slide 8
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 28: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/28.jpg)
Slide 11
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 29: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/29.jpg)
Slide 15
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 30: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/30.jpg)
Slide 18
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 31: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/31.jpg)
Slide 19
Presented By Dung Le at 2016 ASCO Annual Meeting
![Page 32: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/32.jpg)
Summary of Pembrolizumab in MSI-H mCRC § PD-1 blockade with pembrolizumab is highly active
in dMMR mCRC § Complete and durable responses are seen in >50%
of patients § 18% have reached the two year mark on tx and
patients are under surveillance § Next/current trials: single agent pembrolizumab in 1st
line MSI-H mCRC, adjuvant trial, pembro + FOLFOX
32
![Page 33: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/33.jpg)
Nivolumab +/- Ipilimumab in mCRC
33
![Page 34: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/34.jpg)
Nivolumab ± Ipilimumab in Treatment of Patients With Metastatic Colorectal Cancer With and Without High Microsatellite Instability: <br />CheckMate 142 Interim Results
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 35: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/35.jpg)
Ipilimumab and Nivolumab <br />Mechanisms of Action
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 36: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/36.jpg)
Phase 2 CheckMate 142 Study Design: Microsatellite Stable (MSS) Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 37: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/37.jpg)
Phase 2 CheckMate 142 Study Design: <br />MSI-H Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 38: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/38.jpg)
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab Monotherapy
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 39: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/39.jpg)
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab + Ipilimumab
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 40: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/40.jpg)
Best Reduction in Target Lesion Size <br />in Patients With MSI-H
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 41: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/41.jpg)
OS in Patients With MSI-H<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 42: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/42.jpg)
Treatment-Related Adverse Events <br />in ≥ 15% of Patients With MSI-H
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 43: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/43.jpg)
<br />Summary of Efficacy in Patients With MSS<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
![Page 44: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/44.jpg)
Summary of Nivo +/- Ipi in mCRC § Nivolumab monotherapy and nivo + ipi showed
encouraging activity in MSI-H mCRC (interim analysis) § Responses were durable in MSI-H patients § Tolerable safety profiles but increasing toxicities with
combination therapy, consistent w/ observations in other solid tumors
§ Need final analysis prior to next trials
44
![Page 45: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/45.jpg)
Cobimetinib + Atezolizumab in MSS mCRC
45
![Page 46: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/46.jpg)
Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 47: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/47.jpg)
Slide 3
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 48: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/48.jpg)
Atezolizumab: An Anti-PDL1 Antibody
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 49: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/49.jpg)
PD-L1 and MEK Inhibition: A Rational Combination
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 50: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/50.jpg)
Phase Ib Dose Escalation and Cohort Expansion Study (NCT01988896)
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 51: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/51.jpg)
Safety Summary
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 52: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/52.jpg)
Safety: Treatment-related AEs
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 53: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/53.jpg)
Efficacy: Confirmed Objective Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 54: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/54.jpg)
Efficacy: Change in Tumor Burden
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 55: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/55.jpg)
Efficacy: Duration of Treatment and Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
![Page 56: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/56.jpg)
Summary of Cobi + Atezo in MSS mCRC § Cobimetinib + atezolizumab was fairly tolerated in
pts with refractory MSS mCRC § Combination therapy resulted in higher clinical
response rate (17%) and 6-month OS (72%) than expected with either agent alone
§ Cobi may sensitize tumors to atezo by increasing MHC I expression on tumor cells, promoting intratumoral CD8 T cell accumulation
§ Next/current trial: Phase Ib expansion and phase III trial both ongoing
56
![Page 57: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/57.jpg)
Nivolumab in Metastatic Anal Cancer
57
![Page 58: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/58.jpg)
NCI9673: A Multi-Institutional ETCTN Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of
the Anal Canal (SCCA) V. Morris1, K. Ciombor2, M.E. Salem3, H. Nimeiri4, S. Iqbal5, P. Singh6, B. Polite7,
D. Deming8, E. Chan9, J.L. Wade10, T.S. Bekaii-Saab2, H.E. Uronis11, M.G. Pasia1, G. Bland1, R.A. Wolff1, A. Ohinata1, C. Ohaji1, J.E. Rogers1, P. Sharma1, C. Eng1
1The University of Texas MD Anderson Cancer Center, Houston, TX; 2The Ohio State University Comprehensive Cancer Center,
Arthur G. James Cancer Hospital, Columbus, OH; 3Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; 5University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; 6Washington University, Siteman Cancer Center, St. Louis, MO; 7The University of Chicago, Chicago, IL; 8University of Wisconsin Hospitals and Clinics, Madison, WI; 9Vanderbilt University Medical
Center, Nashville, TN; 10Cancer Care Center of Decatur, Decatur, IL; 11Duke University Medical Center, Durham, NC
![Page 59: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/59.jpg)
• Approximately 80-95% of cases are linked to infection with human papillomavirus (HPV).
• The role of HPV in the tumorigenesis of SCCA provides rationale for the use of immune checkpoint blockade agents as a novel therapy for treatment of patients with a virally driven disease.
Presented by: Cathy Eng, MD
Rationale for Nivolumab in Metastatic SCCA:
Morris VK et al. The Oncologist, 2015, Sarup-Hansen E et al. J Clin Oncol ,2014
![Page 60: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/60.jpg)
NCI#9673: Phase II Design of Nivolumab in Metastatic SCCA
Presented by: Cathy Eng, MD
Patients with metastatic squamous cell carcinoma of the anal canal - Treated with at least one prior therapy for metastatic disease
- No prior immune therapies received as part of cancer treatment
12 patients treated initially with nivolumab 3mg/kg IV every 2 weeks
Patients will be followed for best response using RECIST criteria 1.1
0 responses ≥1 response
Stop trial Expand trial to include 25 additional patients with
metastatic SCCA
* HIV+ patients allowed
• Rapid enrollment in < 6 months • Closed to enrollment as of 11/01/15
• Simon Optimal, two-stage phase II study, Ho: p ≤ 0.05 and an alternative hypothesis Ha: p ≥ 0.20,
• α = 0.10 and a β = 0.10
![Page 61: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/61.jpg)
Primary Endpoint: Response Rate
Presented by: Cathy Eng, MD
Response Rate N (%)
CR 2 (5.4%)
PR 7 (18.9%)
SD 17 (45.9%)
PD 8 (21.6%)
Unevaluable 3 (8.1%)
ORR (ITT, N=37) 9 (24.3%)
ORR (Evaluable, N=34) 9 (26.5%)
Data cutoff date: 5/15/16
![Page 62: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/62.jpg)
-1 0 0-9 0-8 0-7 0-6 0-5 0-4 0-3 0-2 0-1 0
01 02 03 04 05 06 07 08 09 0
1 0 0
P a tie n t
% t
arg
et
les
ion
re
du
cti
on
fro
m b
as
eli
ne
by
RE
CIS
T 1
.1 P ro g re s s iv e D is e a s e
S ta b le D is e a s e
P a rt ia l R e s p o n s e
P R
P D
NCI#9673: Response Rate
N=37 (ITT) N=34 (evaluable for RR) 2 CR’s 7 PR’s
Presented by: Cathy Eng, MD
Patients
CR
![Page 63: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/63.jpg)
NCI#9673 Toxicities of Therapy Toxicity (N=37) Grade (%)
1 2 3 4
Fatigue 17 (46) 7 (19) 1 (3) -
Anemia 13 (35) 11 (30) 2 (5) -
Rash 8 (22) 2 (5) 1 (3) -
Constipation 8 (22) 2 (5) - -
Diarrhea 8 (22) - - -
Anorexia 5 (14) 4 (11) - -
Weight loss 5 (14) 1 (3) - -
Arthralgia 3 (8) 3 (8) - -
Hyperglycemia 3 (8) 1 (3) - -
Lymphedema 1 (3) 1 (3) - -
Pneumonitis - 1 (3) - -
Nausea 2 (5) - - -
Hypothyroidism 1 (3) 1 (3) 1 (3) -
Presented by: Cathy Eng, MD
![Page 64: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/64.jpg)
Summary of Nivolumab in Anal Cancer § First prospective phase II trial completed in refractory
mSCC of anal canal; <6 month accrual § Encouraging response rates in a “rare” cancer with
few treatment options for metastatic disease § Nivolumab was well tolerated, even in HIV+ patients § Future trial: amendment of NCI 9673—pilot of
nivolumab + ipilimumab
64
![Page 65: ASCO Review 2016 Colorectal Cancer](https://reader031.fdocuments.in/reader031/viewer/2022022412/58f9b269760da3da068bcb1a/html5/thumbnails/65.jpg)
Thank You To learn more about Ohio State’s cancer program, please visit cancer.osu.edu or
follow us in social media:
65